APA (7th ed.) Citation

X, L., Y, L., H, L., H, L., J, Y., P, H., . . . D, L. (2021). Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. Frontiers in endocrinology, 12, 694390. https://doi.org/10.3389/fendo.2021.694390

Chicago Style (17th ed.) Citation

X, Liu, Liu Y, Liu H, Li H, Yang J, Hu P, Xiao X, and Liu D. "Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes." Frontiers in Endocrinology 12 (2021): 694390. https://doi.org/10.3389/fendo.2021.694390.

MLA (9th ed.) Citation

X, Liu, et al. "Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes." Frontiers in Endocrinology, vol. 12, 2021, p. 694390, https://doi.org/10.3389/fendo.2021.694390.